PURPOSE To study the changes in macroprolactinomas during long-term bromocriptine
therapy by means of serial MR imaging, and to correlate the findings to the serum prolactin …

Objective: Cabergoline is the treatment of choice for prolactin (PRL)-producing pituitary
adenomas, because of its efficacy in normalizing PRL levels, and inducing tumor shrinkage …

Thirty patients with macroprolactinomas were treated with dopaminergic drugs from a
minimum of 4 months to a maximum of 6 years. Tumor size was evaluated with serial CT …

Abstract Three cases (2 men, 1 woman) of expansive macroprolactinoma treated with a
single 50-mg intramuscular dose of a new form of injectable, long-acting bromocriptine are …

To assess the effectiveness of bromocriptine (BRC) as primary therapy in reducing the size
of PRL-secreting macroadenomas with extra-sellar extension, we conducted a multicenter …

The long-term effect of radiotherapy and bromocriptine treatment was retrospectively
evaluated in 25 patients who had previously undergone transsphenoidal surgery for …

Objective Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them
the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow …

OBJECTIVES: Retrospective follow-up study on patients suffering from macroprolactinomas
which were treated with agonists of D2 receptors; the MRI results were correlated with the …

Objective: To assess volumetric changes of pituitary prolactinomas, we applied a threshold-
based segmentation algorithm in two patients during intramuscular bromocriptine treattnent …

Nineteen patients, seven women and twelve men, with macroprolactinomas characterized
by extrasellar extension and basal prolactin levels above 6 U/I were treated with 10-20 mg …